Irritable Bowel Syndrome Clinical Trial
Official title:
Pilot Study Using a Dietary Intervention for Children With Irritable Bowel Syndrome
Malabsorption of certain foods (e.g. lactose) has been proposed as a cause of irritable bowel
syndrome in adults and children. Recently, a diet that lowers intake of a combination of
foods has been found to be effective in adults with IBS identified with fructose
malabsorption.
The purpose of this study is to determine whether a restricted fermentable substrate diet is
effective in the treatment of irritable bowel syndrome in children.
Up to 19% of school-aged children have recurrent abdominal pain (RAP), accounting for 5% of
all pediatric office visits and increased morbidity. The majority of children with RAP have
irritable bowel syndrome (IBS) with up to 60% these children going on to develop IBS as
adults. IBS accounts for up to 8 billion dollars a year of healthcare costs in adults within
the United States. Successful interventions that ameliorate symptoms in childhood IBS may
have an impact into adulthood, however current clinical interventions are often ineffective.
As in adults, the etiology of childhood IBS is multi-factorial, with food intolerance and
increased gastrointestinal inflammation being potential factors. Another factor, that of
malabsorption of fermentable substrates (e.g., fructose), has frequently been postulated as a
form of food intolerance that exacerbates IBS symptoms in adults and children. Studies
suggest up to 61% of children with RAP have fructose malabsorption. The interactions between
factors such as increased gastrointestinal inflammation and malabsorption of fermentable
substrates and they relate to an individual patient is currently unknown.
Recently, a diet that lowers intake of a combination of foods has been found to be effective
in adults with IBS identified with fructose malabsorption. This diet has not been used in
children with IBS nor has its mechanism(s) of efficacy been explored. This pilot project
focuses on using a restricted fermentable substrate diet as a treatment in children with IBS,
while evaluating decreased bacterial fermentation gas production and decreased
gastrointestinal inflammation as mechanisms of its effect.
Using a prospective, open label design in children meeting Rome III childhood IBS criteria,
our Specific Aims are to: 1) Characterize the effectiveness of a restricted FODMAPs diet in
improving symptoms (number of abdominal pain episodes; primary endpoint); 2) To determine the
mechanisms by which a restricted FODMAPs diet may work. We Hypothesize that: 1) A restricted
FODMAPs diet will improve abdominal pain symptoms associated with childhood IBS and
identified fructose malabsorption; 2) A restricted FODMAPs diet will improve symptoms in part
by decreasing bacterial fermentation gas production amongst other potential mechanisms.
The results of this proposal may, if applied on a larger scale, aid a large number of
children with IBS and potentially provide insight into the mechanism(s) behind successful
dietary interventions for childhood IBS.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
| Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
| Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
| Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
| Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
| Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
| Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
| Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
| Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
| Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
| Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
| Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
| Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
| Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
| Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
| Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
| Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A | |
| Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 |